EUVIMEDEUVIMED entdecken
Crossref

Egg Microneedle for Transdermal Delivery of Active Liraglutide

Jeongyun You, Seorin Juhng, Jieun Song, Jihyun Park, Mingyu Jang, Geonwoo Kang, Huisuk Yang, Hye Su Min, Jiwoo Shin, Seri Lee, Hyuk Wan Ko, Hyungil Jung iD

Advanced Healthcare Materials · 2023-04 · 12 (9)

DOI: 10.1002/adhm.202202473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.01.2023. Verfasst von Jeongyun You und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Yonsei University, Building 123, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. Hauptthemen laut MEDLINE: Liraglutide, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liraglutide, a human glucagon‐like peptide‐1 (GLP‐1) analog, is promising for safely treating type 2 diabetes mellitus (T2DM), compared to insulin, by significantly reducing the risk of glucose‐dependent hypoglycemia. Concerns related to injection prevent T2DM patients from taking liraglutide regularly, even though once‐a‐day subcutaneous (SC) injections. Dissolving microneedles (DMNs) are promising substitutes for SC injection and for improving patient convenience. However, there are two fundamental limitations: the low drug delivery due to incomplete insertion and loss of drug activity during DMN fabrication. Here, it is shown that an egg microneedle (EMN) designed with three functional layered structures can maintain the maximum activity of the loaded compound during DMN fabrication and deliver it completely into the skin, with the base layer allowing the complete delivery of liraglutide, and the shell layer maintaining the drug activity by mimicking the role of albumin in eggs. In a diabetic mouse model, liraglutide administration via EMN exhibited similar effect when compared to that of injection. Therefore, EMN‐mediated liraglutide administration is a good potential option for replacing liraglutide injections in T2DM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideDiabetes Mellitus, Type 2MiceAnimalsHumansAdministration, CutaneousSkinGlucagon-Like Peptide 1

Stichwörter der Autor:innen

drug stabilityliraglutidemicroneedlestransdermal drug deliverytype 2 diabetes

Substanzen

LiraglutideGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Biotechnology, Yonsei University, Building 123, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
  • Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
  • Juvic Inc, 272 Digital-ro, Guro-gu, Seoul, 08389, Korea.

ORCID-Profile: Hyungil Jung

Förderung

  • National Research Foundation of Korea

Zitieren

APA

You, J., Juhng, S., Song, J., Park, J., Jang, M., Kang, G., Yang, H., Min, H. S., Shin, J., Lee, S., Ko, H. W., & Jung, H. (2023). Egg Microneedle for Transdermal Delivery of Active Liraglutide. Advanced Healthcare Materials, 12(9). https://doi.org/10.1002/adhm.202202473

Vancouver

You J, Juhng S, Song J, Park J, Jang M, Kang G, et al. Egg Microneedle for Transdermal Delivery of Active Liraglutide. Advanced Healthcare Materials. 2023;12(9). doi:10.1002/adhm.202202473

BibTeX
@article{You2023,
  author = {You, Jeongyun and Juhng, Seorin and Song, Jieun and Park, Jihyun and Jang, Mingyu and Kang, Geonwoo and Yang, Huisuk and Min, Hye Su and Shin, Jiwoo and Lee, Seri and Ko, Hyuk Wan and Jung, Hyungil},
  title = {Egg Microneedle for Transdermal Delivery of Active Liraglutide},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  volume = {12},
  number = {9},
  doi = {10.1002/adhm.202202473}
}
Kostenlos starten →